Rosetta Genomics Expands Molecular Diagnostics Test Menu with Launch of OncoGxSelect™ from Admera Health
August 04 2016 - 8:15AM
Business Wire
New NGS-based Assay Increases Number of Genes
Examined for Lung Cancer and Other Solid Tumor Types
Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and
provider of microRNA-based and other molecular diagnostics,
announces the launch of OncoGxSelect™, a next generation sequencing
(NGS)-based test that detects somatic mutations frequently found in
cancers and provides actionable results to help guide therapeutic
decisions related to targeted cancer therapies.
OncoGxSelect™ leverages Admera Health’s industry-leading NGS
technology and interrogates 12 genes implicated in highly-prevalent
lung cancer types: ALK, BRAF, EGFR, ERBB2, KIT, KRAS, MAP2K1, MET,
NRAS, PIK3CA, RET and ROS1. OncoGxSelect™ is a significant upgrade
to OncoGxLung as it increases the number of genes examined from 5
to 12, and has the capacity to be used for other tumor types based
on important mutations found in various cancers such as thyroid
cancer.
OncoGxSelect™ targets the genes included in nationally accepted
clinical guidelines for molecular testing, and establishes a much
more attractive opportunity with greater potential for favorable
reimbursement.
“Lung cancer is one of the most prevalent cancers worldwide. The
commercial launch of this advanced test provides a more
comprehensive set of actionable information for the oncologists and
pathologists we serve, and adds to a comprehensive lung-specific
menu that assists in answering the most difficult clinical
questions clinicians face when treating these patients,” stated
Kenneth A. Berlin, President and Chief Executive Officer of Rosetta
Genomics. “The OncoGxSelect™ test adds to the growing number of
services we offer, and further establishes Rosetta Genomics as a
leader in delivering personalized diagnostic testing.”
Guanghui Hu, PhD, President and CEO of Admera, elaborated, “The
development of this OncoGxSelect™ panel and our continued
relationship with Rosetta Genomics will increase patient access to
cutting edge sequencing diagnostics, advancing precision medicine
by providing oncologists with a tool to guide targeted therapy
treatment decisions.”
About Admera Health
Admera Health is an advanced molecular diagnostics company
focused on personalized medicine, non-invasive cancer testing and
digital health. Dedicated to developing cutting-edge diagnostics
that span the continuum of care, Admera Health fulfills unmet
medical needs with cost-effective tests and accurate analysis to
guide patient care. Utilizing next generation technology platforms
and advanced bioinformatics, Admera Health seeks to redefine
disease screening, diagnosis, treatment, monitoring, and management
through its innovative, personalized solutions. It is our mission
to deliver transformative, valuable solutions for patients,
physicians, and clinical researchers. We are committed to improving
the health and well-being of our global community through the
direct delivery of personalized, medically actionable results.
About Rosetta Genomics
Rosetta develops and commercializes a full range of
microRNA-based and other molecular diagnostics. Rosetta’s
integrative research platform combining bioinformatics and
state-of-the-art laboratory processes has led to the discovery of
hundreds of biologically validated novel human microRNAs. Building
on its strong patent position and proprietary platform
technologies, Rosetta is working on the application of these
technologies in the development and commercialization of a full
range of microRNA-based diagnostic tools. Through the acquisition
of PersonalizeDx, the Company now offers core FISH, IHC and
PCR-based testing capabilities and partnerships in Pathology,
Oncology and Urology that provide additional content and platforms
that complement Rosetta’s microRNA and Next-Gen Sequencing
offerings. RosettaGX Reveal™, a Thyroid microRNA Classifier for the
diagnosis of indeterminate thyroid FNA smears, as well as the full
RosettaGX™ portfolio of cancer testing services are commercially
available through the Company’s Philadelphia, PA- and Lake Forest,
CA-based CAP-accredited, CLIA-certified labs. For more information
visit www.rosettagx.com.
Forward-Looking Statement Disclaimer
Various statements in this release concerning Rosetta’s future
expectations, plans and prospects including, but not limited to
statements relating to the increased potential of our commercial
and reimbursement efforts, and our continuing relationship with
Admera constitute forward-looking statements for the purposes of
the safe harbor provisions under The Private Securities Litigation
Reform Act of 1995. Actual results may differ materially from those
indicated by these forward-looking statements as a result of
various important factors, including those risks more fully
discussed in the "Risk Factors" section of Rosetta’s most recently
filed Annual Report on Form 20-F, as filed with the SEC. In
addition, any forward-looking statements represent Rosetta’s views
only as of the date of this release and should not be relied upon
as representing its views as of any subsequent date. Rosetta does
not assume any obligation to update any forward-looking statements
unless required by law.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160804005669/en/
Rosetta GenomicsKen Berlin, President & CEO(267)
298-1159investors@rosettagx.comorAdmera HealthBrady
Millican, VP Business
Development908-222-0533brady.millican@admerahealth.comorRosetta
Genomics InvestorLHAAnne Marie Fields(212)
838-3777afields@lhai.com
Rosetta Genomics (CE) (USOTC:ROSGQ)
Historical Stock Chart
From Aug 2024 to Sep 2024
Rosetta Genomics (CE) (USOTC:ROSGQ)
Historical Stock Chart
From Sep 2023 to Sep 2024